Dramatic changes in the stem cell ethical and research ecosystem in the last 10 years depended on active engagement among scientists, ethicists, government, and public. Tracing that story demonstrates the value of such engagement, and forecasts a successful method for meeting future challenges.
Finally, it's 2011, and stem cell research is facing a somewhat friendly world. In the U.S., with the stroke of an appellate court's pen, federal funds for embryonic stem cell research can now flow as the new President and past Congresses intended-at least until the next judicial bump in the road. As this year's annual ISSCR meeting will show, research is pursued in almost countless directions, connecting the dots scientifically from pluripotency to differentiation. Within and across specialties and countries, new knowledge concentrates and diffuses; in some areas, there is the palpable tension preceding another breakthrough.
But think back on the environment only 10 years ago. A global patchwork of irreconcilable political divides. High-risk legal pitfalls for the unwary. Unbridgeable ethical positions, not just around derivation, but around research uses and appropriate scientific methods. Would stem cell research be The Abortion Debate, Part II? Add in stifling intellectual property restrictions, which limited commercial research sponsorship at the same time government funding was scarce. In the U.S., a wellintentioned attempt by President Bush to craft a funding compromise, around few cell lines, satisfied few. Groundless hype floated beside prophetic science, and there was no clear way for the public to tell the difference, or know what interesting experiment would pop up next on the front page of a national newspaper: successful human cloning? Dolly the sheep replaced by a scientifically caged Dolly the human, a clone exploited to supply organs to a failing body? Human DNA in bovine eggs? ''Chimeric minotaurs feared,'' said the Australian press. Surely these were events described by Nostradamus or Bosch, or in prophecies of the Apocalypse. Would stem cell scientists, eyes aglimmer, remember or forget what we all have learned time and again: that new science and new technology always, eventually, take on a life of their own, in ways we do not predict?
Yet here we are-no minotaurs in evidence; no stem cell civil war. To the contrary, we have an extraordinary degree of pluralistic consensus, and an intertwined scientific and ethical path forward that was unthinkable in 2001. Has it really been just 10 years? What did it take? And what will it take, for the challenges that remain?
We have all heard the arguments for scientists to engage responsibly with the public over the aims, norms, and social consequences of their work. I have made such arguments myself; as I wrote in 2007, ''Abandoning real public engagement is not ending it. It is abandoning it to the forces scientists fear.'' (Taylor, 2007) . And we have all heard the arguments why scientists can ignore social implications: ''knowledge'' is science's business, and science is unconstructed and value free: leave consequences to others. We will not replay those tapes here. Instead, this is an opportune time to make a different argument, an argument from looking back, concerning the bridge that scientists and society must construct together, when biological novelty challenges the public and personal senses of self and society. On what did this social and scientific transformation rest? Is it complete? What remains to be done?
It rested on this: devotion to actively engaging with public discussion and personal responsibility, over hard issues, leading to the ISSCR's unusual step to donate its expertise to patients seeking help, by turning the light of its own inquiry on commercial purveyors of unproven therapies . This sort of engagement is not abstract. It proceeded from real awareness that one false step could end a career and a field. It went beyond downloading ''facts'' and theories to a public often portrayed as scientifically Luddite; this was no simple picture of the Light of Reason dispelling the Darkness of Ignorance. There was more serious listening, within a shared public-scientific sphere, and joint tinkering with how concerns were framed and solutions proposed. More caring about those whose lives could be affected-from embryonic ones to adult ones-sufficient to cut across partisan politics. More insight that the autonomy of science depends on the moral authority of its actors, and that that moral authority is earned through interaction, not through disengagement or pronouncements that reduce normative positions to empirical ones. More mutual recognition of pluralistic values inevitably in tension, a tension to be lived with and acted through, not ended through some ideological or pragmatic victory. More mutual querying of the aims and limits of science; and more joint acknowledgment of uncertainties and where self-regulation might focus, than denials and false certainties. More sense of joint ownership and therefore joint commitment to future research. The point is this: through such means is the social context for cutting-edge science built. Nothing less.
Ten Years Ago
Although there are many planes along which we might observe, let's take three accessible ones, summarized in Table 1,  Table 2, and Table 3 . Discussion among ethicists, and to some extent the public, focused on the ethics of derivation. Yet other ethical issues emerged early and were not forgotten. Positions clustered around distinct avenues: the absolute, noncontingent prohibition on embryo destruction for stem cell research, to staged equations of embryonic rights against actual capacity or developmental potential, theoretical or real. All but the first position could envision some circumstances under which embryonic stem cell derivation would be ethical, provided that the intentions and actual benefits of doing so were aligned around healing, particularly in connection with pathologies not presently treatable. At the other extreme, all could also envision some circumstances, and some forms of embryonic stem cell research, that would be wrong or even morally catastrophic.
With ethics depending on conditions and consequences, in fact, identifying ethical conditions, and assuring their occurrence, was widely seen as an essential task. What are the legitimate powers of donors? Can one create embryos for the purpose of research, or may research be conducted only on those already fated for destruction through independent choice? How long is too long to maintain an embryo in vitro? Do research methods matter? In what ethical environment must research occur? How should these questions be answered-within the disciplines of bioethics or developmental biology, or across disciplines and with public input? Would answers come from extrapolating from past intuitions or from listening to current and public ones as well?
Ensuring that the benefit would be real meant that intellectual property became compellingly relevant to practical ethics. Forget pretending, on one side, that the public will benefit, while, on the other, insulating intellectual property decisions from popular sentiment or practical effect behind the walls of government patent offices and university tech transfer seeking profit over benefit. The ideals of the scientific community and the discipline of socially just access become linked to the ethical legitimacy of the research itself.
Yet, the effect of federal funding policy was that the key regulatory foundations for ethical scientific research did not apply to most stem cell research, precisely because the whole structure of data and materials sharing, research integrity and misconduct, and ethical review is linked to federal funding (see Table 4 ). If ethical review and property were to be regulated, they had to be self regulated, or they would not be regulated at all. But this would be self regulation in the public eye, not behind the closed doors of a conference retreat, self-regulation which would be critiqued in newspapers and leading journals, and would answer, or obviously fail to answer, the stated concerns of diverse members of the public, and government members of all parties and persuasions, and globally so, not just locally.
So while U.S. law fumbled on, coarsely translating ethical nuance into what to fund, and nations and states diverged, extraordinary discussion bypassed the ordinary organs of democratic government. Mechanisms for the generation of standards evolved. Some, like standards of the U.S. National Academy of Sciences (NAS), were precise, professional, and not initially particularly democratic, involving the application of proficient and conscientious expertise to creating standards for the ethical conduct of stem cell research, addressing problems perceived and, with deep insight, some yet to be perceived. The standards of the International Society for Stem Cell Research (ISSCR) (Daley et al., 2007; Hyun et al., 2008; Taylor et al., 2010 ) was a comparable effort, but with four significant differences. First, the effort was deliberately global from inception to application. Second, it invited public comment. The result of the latter was unmistakable: drafts and redrafts, discussions and rediscussions, around how problems and solutions were perceived and articulated, and whether justifications spoke not only Neuron to those who would agree, but to those who would disagree; if not persuasive, then at least arguments were taken seriously. Third, it conceived ethics broadly, addressing not just laboratory minutiae, but social justice in research choices, broad access to stem cell therapies, and intellectual property and data sharing among haves and have-nots. It translated theory into imperatives, so the norm of universal sharing, explicitly expressed, was translated into specific institutional obligations and concrete applications like model consent documents and model materials transfer agreements, which were transparent for public feedback. Fourth, longitudinally, it did not stop at the lab door, but tried to trace the trajectory from basic research through translation to clinical research, medical innovation, and-their snake-oil-bearing, false cousin-the sale of unproven therapies as cures to desperate patients and their families.
The ISSCR and NAS were hardly alone in this effort (Taylor, 2010) . Leading journals not only publicized these efforts, but critiqued them, directly and indirectly, and countered. Some government agencies, particularly in the U.K., experimented and taught, while other government branches inquired and challenged. Crossing national lines, consortia like The Hinxton Group engaged in focused attention on transnational cooperation and special issues like gamete production and new ways to decrease the barrier effect of intellectual property on global justice and innovation (The Hinxton Group, 2006 Group, , 2008 Group, , 2011 . Nascent stem cell review and oversight committees began the hard work of protocolspecific review, feeding back what worked and what failed among new standards. Organizations like Public Responsibility in Medicine and Research (PRIM&R) directed some of their extraordinary organizational and educational skills to shared policy-making, discussion, and evaluation. European and North American stem cell banks and registries, networks, and consortia of networks, in consultation with scientists, government, and public, began to formalize scientific and ethical requirements that would govern what materials would be banked and distributed, and played a critical role in interacting with desperate patients and formulating a response. Some politicians made it a hallmark of their integrity to develop nuanced positions, neither disrespectful of their opponents nor shallow in thinking through what they believed.
The Effect
The effect is what we have today. In public ethics, there is nuanced support for a range of options, but primarily for research on stored IVF embryos initially created for reproduction, that will not, through parental choice, be implanted, and subject to the parents' specific donation for research. Few regard this decision, or the consensus, lightly. There are consensus standards on most ethical issues involving the original donation, informed consent, and provenanceincluding criteria shared among public, scientists, stem cell banks, and registries and independent ethical review bodies. There are ethical standards for chimera research, revisable as the characteristics of chimeras become known, and there is as active search for factual characteristics that would make normative differences. Guidance addresses almost every issue in Table 1 . Self-regulatory guidance, administered through self-regulatory committees with public membership, remains, though, as the major source of practical ethics.
The combination of standards, peer pressure, leadership changes, and scientific developments has altered the intellectual property landscape completely. The main human embryonic stem cell patent holder retreated from requiring academic licenses; multiple ''technologies,'' including nonpluripotent derivatives and induced pluripotent cells, reduced the impact of the human embryonic stem cell patent position; and other patent holders tacitly follow a different course of tolerating academic unlicensed use.
Recognition of health risks has led to intertwining ethical concerns with lines of further research. Thus, researchers have directed their attention to genes and factors affecting cancer risks and uncontrolled development and the development of pluripotent alternatives with select oncogene deletions for induced pluripotent cells, have adopted as a foundation the tissue regulatory framework useful elsewhere, and, most importantly, have reached scientific and ethical agreement on a strict, transparent, data-based, and controlled translational and clinical research pathway, without shortcuts, as the basis for any human applications of human embryonic stem cells or direct derivatives.
The latter became the technical foundation for the ISSCR's outreach to commercial purveyors of stem cell therapy. But the moral and political foundation was necessarily broader, requiring ''the essential relationship that exists between scientific progress and public responsibility,'' and ''the long-standing commitment of the ISSCR to ethical and scientific self-regulation through globally representative consensus on standards that distinguish sound and ethical stem cell science from practices that would be unethical or unsound.'' Many challenges remain, both for this research and for policy-making (Zarzeczny et al., 2009) . Some are old at root but new in dimensions, such as protecting desperate patients from facile consent to unworthy experiments. Some are larger, such as giving meaning to justice, and keeping foundational ethical commitments to ensuring that both benefits and risks are actually fairly distributed across society. Some are larger still, and entail perfecting and employing, consistently, what Jasanoff (2003) has baptized ''technologies of humility,'' specified social technologies Materials transfers, data sharing, and patent uses restricted Commercially funded research financially constrained by holder of stem cell patents through unique academic and commercial license restrictions, but not constrained by federal standards of scientific ethics for democratic interengagement-or is it intraengagement?-with science.
As a participant in the history above, I no doubt have brought to the analysis my own misperceptions and biases, but I have no apologies, for its essential lesson is true and clear, and marks the difference between where we were and where we may yet fully arrive, through active and deep commitments to public engagement.
